Open Access<p>Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives</p>
Author(s) -
Sabrina Zulfikar,
Sarah Mulholland,
Huzaifa Adamali,
Shaney Barratt
Publication year - 2020
Publication title -
clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.685
H-Index - 27
ISSN - 1179-1438
DOI - 10.2147/cpaa.s228362
Subject(s) - autotaxin , lysophosphatidic acid , medicine , interstitial lung disease , disease , clinical trial , lung , fibrosis , idiopathic pulmonary fibrosis , receptor
Idiopathic pulmonary fibrosis is a progressive fibrosing interstitial lung disease for which there is no known cure. Currently available therapeutic options have been shown at best to slow the progression of the disease and thus there remains an urgent unmet need to identify new therapies. In this article, we will discuss the mechanisms of action, pre-clinical and clinical trial data surrounding inhibitors of the autotaxin-lysophosphatidic acid axis, which show promise as emerging novel therapies for fibrotic lung disease.